Both in Biotechnology
Exelixis vs ImmunityBio
Over the past year EXEL returned +63.8% and IBRX returned +232.9%; their daily moves had a correlation of 0.16.
EXEL +63.8% IBRX +232.9%Growth of $1, one year, split-adjusted
| Metric | EXEL | IBRX |
|---|---|---|
| Price | $65.66 | $8.59 |
| Market cap | $16.27B | $9.10B |
| Today | −0.94% | −2.50% |
| 1 month | +12.4% | −9.0% |
| 6 months | +47.7% | +21.0% |
| Year to date | +49.8% | +333.8% |
| 1 year | +63.8% | +232.9% |
| Revenue growth (YoY) | +10.6% | +93.9% |
| Gross margin | 96.7% | 99.4% |
| Net margin | 33.7% | −449.6% |
| P/E (TTM) | 18.9× | — |
| Price / sales | 6.7× | 54.9× |
| Net cash | $839.4M | -$57.7M |
| Dividend yield | — | — |
| Volatility (60d) | 31.5% | 67.3% |
| Short % of float | 11.4% | 31.1% |
| Next earnings | — | — |
Shading marks the stronger figure where one clearly exists (lower is better for valuation and volatility).